常见产品
Common Products
相关产品
「同位素标记抑制剂」Cilnidipine-d7
- 产品货号:E-T202508210001
- 发布时间:2025-08-21
- 产品CAS :N/A
- 产品规格:mg
- 产品纯度:≥95%
- 产品货期:现货下单后48小时内发货,定制产品4-8周。
- 运输条件:顺丰常规运输
产品详情
货号:E-T202508210001
CAS:N/A
规格:mg
纯度:≥95%
生产商:试剂家
生物活性:Cilnidipine-d7 is deuterium labeled Cilnidipine. Cilnidipine is a long-acting, second-generation dihydropyridine Ca2+-channel blocker on L and N-type Ca2+ channel[1][2][3][4]. Antihypertensive effects[5].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Cilnidipine-d7 相关抗体:
Annexin VI Antibody
Calbindin Antibody
Calreticulin Antibody
Cardiac Troponin I/TNNC1 Antibody
SCGN Antibody (YA1167)
RAMP1 Antibody (YA1818)
Annexin V Antibody (YA1829)
Striatin 4 Antibody (YA2088)
Fibulin 5 Antibody (YA2448)
RASGRP1 Antibody (YA2546)
Fibulin 1 Antibody (YA2831)
EFEMP1 Antibody (YA2883)
CRCP Antibody (YA3350)
Annexin VII Antibody (YA1138)
Parvalbumin Antibody (YA1249)
Annexin IV Antibody (YA1921)
SERCA2 ATPase Antibody (YA1931)
Stromal Interaction Molecule 1 Antibody (YA2092)
SERCA1 ATPase Antibody (YA2157)
TrpV5 Antibody (YA2284)
NCX1 Antibody (YA2331)
Scramblase 1 Antibody (YA2419)
CAB39 Antibody (YA2761)
CUG BP1 Antibody (YA2806)
C10orf63 Antibody (YA2894)
ITPK1 Antibody (YA3125)
ORAI3 Antibody (YA3128)
ORAI1 Antibody (YA3157)
CREB Regulated Transcription Coactivator 2 Antibody (YA3279)
分子量:499.56
Formula:C27H21D7N2O7
非标记 CAS:132203-70-4
中文名称:西尼地平-d7
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (527 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]
[2]. S Fujii,et al. Effect of cilnidipine, a novel dihydropyridine Ca2+-channel antagonist, on N-type Ca2+ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997 Mar;280(3):1184-91.
[Content Brief]
[3]. Matthias Löhn, et al. Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J Hypertens. 2002 May;20(5):885-93.
[Content Brief]
[4]. Young Joo Lee, et al. Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J Neurochem. 2009 Oct;111(1):90-100.
[Content Brief]
[5]. Naresh Kumar, et al. Anti-stress effects of cilnidipine and nimodipine in immobilization subjected mice. Physiol Behav. 2012 Mar 20;105(5):1148-55.
[Content Brief]
[6]. A Takahara, et al. [Antihypertensive effects of repeated oral administration of cilnidipine, a novel calcium antagonist, in 2K1C renal hypertensive dogs]. Nihon Yakurigaku Zasshi. 1995 Oct;106(4):279-87.
[Content Brief]
在线留言
欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。